Related Experiment Videos
Inappropriate antidiuretic hormone secretion after high-dose thiotepa
1Divisione Ematologia, Istituto di Semeiotica Medica, Università Cattolica Sacro Cuore, Rome, Italy.
Bone Marrow Transplantation
|September 14, 1999
Summary
High-dose thiotepa, used in stem cell transplants, can cause severe side effects. This case highlights a rare instance of Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) following this intensive therapy.
Area of Science:
- Oncology
- Hematology
- Nephrology
Background:
- High-dose thiotepa is a common chemotherapeutic agent used in conditioning regimens for stem cell transplantation.
- Its known toxicities include myelosuppression and potential liver damage.
- Primary central nervous system (CNS) lymphoma is a rare but aggressive malignancy.
Observation:
- A patient with primary CNS lymphoma received high-dose thiotepa as part of their conditioning regimen.
- The patient developed symptoms suggestive of a specific endocrine-related complication.
Findings:
- The patient was diagnosed with Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH).
- This represents a rare adverse event associated with high-dose thiotepa therapy.
- SIADH is characterized by excessive water retention and hyponatremia.
Implications:
- Clinicians should be aware of SIADH as a potential complication of high-dose thiotepa.
- Monitoring electrolyte balance is crucial in patients undergoing this treatment.
- Further investigation may be warranted to understand the mechanism linking thiotepa and SIADH.